Global Radiopharmaceuticals Market Product Development and Treatment Analysis by Top Competitors
Global Radiopharmaceuticals Market: Information by Type (Diagnostic (SPECT Radiopharmaceuticals, PET Radiopharmaceuticals) and Therapeutic), Application (Neurology, Cardiology, Oncology and others) and Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2025
Global Market - Overview
Global Radiopharmaceuticals Market is expected to register a CAGR of 8.10% during the
forecast period, with a market value of USD 15,060.87 Million till
2025.
Radiopharmaceuticals are radioactive compounds or
nuclear medicines that find diagnostic and therapeutic applications in the
medical industry. The radioactive particles are used in medical imaging to
diagnose diseases and to treat cancer through targeted therapy.
Avail
a Free Sample@ https://www.marketresearchfuture.com/sample_request/1650
The global radiopharmaceutical market is expected
to exhibit an exponential growth during the forecast period, owing to the increasing
prevalence of chronic diseases such as cancer, the growing use of radioisotopes
in the healthcare industry, increasing application of radiopharmaceuticals for
the diagnosis & treatment of chronic diseases, and the technological
advancements in diagnostics sector.
However, factors such as the short half-life of
radiopharmaceuticals and its high cost are likely to restrain the market
growth. Other factors restraining the market growth are side-effects of
radiopharmaceuticals and strict regulations pertaining to their manufacturing.
Segment Analysis
The Global Radiopharmaceuticals Market, by type,
has been divided into diagnostics, and therapeutic. The diagnostics
segment is further segmented into SPECT radiopharmaceuticals and PET
radiopharmaceuticals. SPECT radiopharmaceuticals are classified into Tc99m,
I-123, and Others. PET radiopharmaceuticals segment is bifurcated into F18, C11
Choline, and Others. The radioactive tracer (radiopharmaceutical) is given
to the patient by intravenous injection, orally, or by other routes depending
on the organ and the function to be studied. In developed countries about one
in 50 persons are found to undergo diagnosis using radiopharmaceuticals each
year. The growing importance of diagnostic radiopharmaceuticals to predict the
effects of surgery and assess the changes is anticipated to drive the growth of
this segment during the forecast period.
The Global Radiopharmaceuticals Market, by
application segment, has been segmented into neurology, cardiology, oncology,
and others. The neurology is the largest segment in the global
radiopharmaceuticals market. The rising prevalence of neurological disorders is
expected to drive the growth of this segment during the forecast period.
Regional Analysis
The Global Radiopharmaceuticals
Market, based on region, has been divided into the Americas, Europe,
Asia-Pacific, and the Middle East & Africa.
The Americas accounted for
the largest share in the global radiopharmaceuticals market. The Americas is
further segmented into North America and Latin America. North America is
further divided into the US and Canada. Latin America consists of Mexico,
Brazil, Colombia, Argentina, Chile, Peru, Uruguay, and Venezuela. The
rising demand for non-invasive diagnostics and treatments and the presence of a
vast patient population suffering from chronic diseases are likely to provide
favorable conditions for the growth pf the market.
Europe established
substantial growth in the market and anticipated to register the highest CAGR
during the forecast period. Europe is segmented into Western Europe, Northern
Europe, Eastern Europe, and the Rest of Europe. Rising investment for
research and the presence of a vast patient pool and an increasing number of
radioisotope approvals for different clinical indications are expected to drive
the growth of the market.
The Asia-Pacific market for
radiopharmaceuticals is further divided into Japan, China, Australia, India,
South Korea, South-East Asia, New Zealand, Pakistan, and the Rest of
Asia-Pacific. South-East Asia is further divided into Singapore, Malaysia,
Indonesia, Thailand, Vietnam, and the Philippines. The radiopharmaceutical
companies are expanding their operations in countries such as China, India,
Singapore, and Russia, owing to the cost-efficiency in these
regions. Additionally, Asia-Pacific has a large pool of geriatric
populations requiring invasive therapies for the treatment of the increasing
cases of cardiovascular diseases, neurological diseases, and others. According
to the Economic and Social Commission for Asia and the Pacific (ESCAP) in 2016,
approximately 12.4% of the population in the region was 60 years or older and
is projected to rise to 1.3 billion people by 2050.
The radiopharmaceuticals
market in the Middle East & Africa is expected to grow due to the presence
of developed countries such as Egypt, Saudi Arabia, and others. Additionally,
increasing awareness about radiopharmaceuticals in the region is expected to
contribute to the growth of the market.
Key Findings of the Study
- The Global Radiopharmaceuticals
Market is estimated to grow at USD 15,060.87 million by 2025 at
a CAGR of 8.10% during the assessment period.
- Americas accounted for
the largest share of the global market due to the presence of key market
players and the rising demand for non-invasive diagnostics and treatments.
- Based on the type, the
diagnostics segment accounted for the largest market share of 82.9% in
2018.
- Global
radiopharmaceuticals market on the basis of application is dominated by
neurology segment with 37.8% market share.
Access Report Details @ https://www.marketresearchfuture.com/reports/radio-pharmaceutical-market-1650
The report for Global market by Market
Research Future comprises of extensive primary research along with the detailed
analysis of qualitative as well as quantitative aspects by various industry
experts, key opinion leaders to gain a deeper insight of the market and
industry performance. The report gives a clear picture of the current market
scenario which includes past and estimated future market size with respect to
value and volume, technological advancement, macro economical and governing
factors in the market. The report provides detail information about and
strategies used by top key players in the industry. The report also gives a
broad study of the different market segments and regions.
Key Players
MRFR recognizes the following companies as
the Key Players in the Global Radiopharmaceuticals Market— GE
Healthcare, Lantheus Medical Imaging, Inc., Novartis AG, BWX Technologies,
Inc., Siemens Healthineers, IRE ELiT, JSC Isotope, NTP Radioisotopes SOC Ltd,
Curium, Australian Nuclear Science and Technology Organization (ANSTO), and
others
TOC:
1.
Report Prologue
2. Market
Introduction
2.1
Definition
2.2 Scope of the
Study
2.2.1
Research Objective
2.2.2
Assumptions
2.2.3
Limitations
3. Research
Methodology
3.1 Introduction
3.2 Primary
Research
3.3 Secondary research
3.4 Market Size
Estimation
TOC…Continued
Ask
Questions to Expertise @ https://www.marketresearchfuture.com/enquiry/1650
About Market Research Future:
At Market Research Future (MRFR), we enable our
customers to unravel the complexity of various industries through our Cooked
Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research
Reports (3R), Continuous-Feed Research (CFR), and Market Research &
Consulting Services.
MRFR team have supreme objective to provide the
optimum quality market research and intelligence services to our clients. Our
market research studies by Components, Application, Logistics and market
players for global, regional, and country level market segments, enable our
clients to see more, know more, and do more, which help to answer all their
most important questions.
In order to stay updated with technology and work
process of the industry, MRFR often plans & conducts meet with the industry
experts and industrial visits for its research analyst members.
Contact Us:
Market
Research Future
Office
No. 528, Amanora Chambers
Magarpatta
Road, Hadapsar,
Pune
- 411028
Maharashtra,
India
Phone: +1 646 845 9312
Comments
Post a Comment